---
category: trading
circular_id: 4c469b781f2419fb
date: '2026-01-13'
description: SEBI adjudication order against Ayusri Health Products Limited (previously
  Sahul India Limited) for executing non-genuine reversal trades in illiquid stock
  options at BSE during April 2014 to September 2015, creating artificial volumes.
draft: false
guid: https://www.sebi.gov.in/enforcement/orders/jan-2026/adjudication-order-in-respect-of-ayusri-health-products-limited-in-the-matter-of-illiquid-stock-options-at-bse_99035.html
impact: medium
impact_ranking: low
importance_ranking: medium
justification: Adjudication order against a specific entity for past violations (2014-2015)
  in illiquid stock options. Limited market-wide impact as it addresses historical
  manipulative practices of one company. Importance is medium due to enforcement action
  demonstrating regulatory oversight.
pdf_url: https://www.sebi.gov.in/sebi_data/attachdocs/jan-2026/ORDER_1768293872.pdf
processing:
  attempts: 1
  content_hash: f35284e8d5a9ad12
  processed_at: '2026-01-14T01:53:55.061593'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2026-01-13T00:00:00+05:30'
rss_url: https://www.sebi.gov.in/enforcement/orders/jan-2026/adjudication-order-in-respect-of-ayusri-health-products-limited-in-the-matter-of-illiquid-stock-options-at-bse_99035.html
severity: high
source: sebi
stocks:
- AYUSRI
tags:
- adjudication-order
- stock-options
- illiquid-stocks
- bse
- market-manipulation
- artificial-volume
- reversal-trades
- pfutp-regulations
- enforcement-action
- ayusri-health-products-limited
- sahul-india-limited
title: Adjudication Order in respect of Ayusri Health Products Limited in the matter
  of Illiquid Stock Options at BSE
---

## Summary

SEBI has issued an adjudication order (Order/AK/DS/2025-26/31965) against Ayusri Health Products Limited (previously known as Sahul India Limited, PAN: AADCS7349J) for executing non-genuine reversal trades in illiquid stock options at BSE during the investigation period of April 1, 2014 to September 30, 2015. The entity executed 10 non-genuine trades in 5 stock options contracts, resulting in artificial volume of 38,10,000 units. These trades allegedly violated PFUTP Regulations by creating false or misleading appearance of trading through artificial volumes.

## Key Points

- SEBI investigation revealed 2,91,744 trades (81.40% of all trades) in BSE stock options segment during the investigation period were allegedly non-genuine
- Ayusri Health Products Limited executed 10 reversal trades in 5 stock options contracts
- Total artificial volume created: 38,10,000 units
- Alleged violations: Regulations 3(a), (b), (c), (d), 4(1) and 4(2)(a) of SEBI PFUTP Regulations, 2003
- Show Cause Notice issued on August 5, 2022
- Adjudication proceedings initiated under Section 15-I of SEBI Act, 1992
- Case transferred to new Adjudicating Officer on April 3, 2025

## Regulatory Changes

No new regulatory changes introduced. This order enforces existing provisions of SEBI (Prohibition of Fraudulent and Unfair Trade Practices Relating to Securities Market) Regulations, 2003.

## Compliance Requirements

- Entities trading in stock options must ensure all trades are genuine and not create artificial volumes
- Market participants must avoid reversal trades that create false or misleading appearance of trading
- Compliance with PFUTP Regulations regarding manipulative, fraudulent and deceptive trading practices

## Important Dates

- Investigation Period: April 1, 2014 to September 30, 2015
- Initial AO Appointment: July 26, 2022
- Show Cause Notice Issued: August 5, 2022
- Transfer to New AO: April 3, 2025
- Order Number: Order/AK/DS/2025-26/31965

## Impact Assessment

**Market Impact:** Limited direct market impact as the order addresses historical violations from 2014-2015 in illiquid stock options segment. The case is part of SEBI's broader crackdown on artificial volume creation at BSE.

**Entity Impact:** Ayusri Health Products Limited (formerly Sahul India Limited) faces potential penalties under Section 15HA of SEBI Act for manipulative trading practices.

**Regulatory Significance:** Demonstrates SEBI's continued enforcement against market manipulation schemes, particularly reversal trades in illiquid derivatives that distort market integrity. The investigation covered large-scale manipulation affecting over 81% of trades in the segment during the investigation period.